Bulent Cetin
9PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Jan 22, 2026
First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.Irem Karaman, Dilek Erdem, Bulent Cetin
|Jun 09, 2023
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.Bulent Cetin, Chiara A Wabl, Ozge Gumusay
|Jan 18, 2023
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?Bulent Cetin, Chiara A Wabl, Ozge Gumusay
|Mar 22, 2022
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.Bulent Cetin, Chiara A Wabl, Ozge Gumusay
|Feb 09, 2022
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.Bulent Cetin, Chiara A Wabl, Ozge Gumusay
|Jan 24, 2022
Investigation of anxiety sensitivity levels of cancer patients in terms of COVID-19 vaccine: a cross-sectional study.Gokce Iscan, Bulent Cetin, Faruk Kilic
Pageof 2
